196 related articles for article (PubMed ID: 38349387)
41. Brentuximab vedotin in systemic T-cell lymphoma.
Oki Y; Younes A
Expert Opin Biol Ther; 2012 May; 12(5):623-32. PubMed ID: 22428917
[TBL] [Abstract][Full Text] [Related]
42. Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30-Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial.
Kim SJ; Yoon DH; Kim JS; Kang HJ; Lee HW; Eom HS; Hong JY; Cho J; Ko YH; Huh J; Yang WI; Park WS; Lee SS; Suh C; Kim WS
Cancer Res Treat; 2020 Apr; 52(2):374-387. PubMed ID: 31476851
[TBL] [Abstract][Full Text] [Related]
43. Brentuximab vedotin: a new age in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma.
Minich SS
Ann Pharmacother; 2012 Mar; 46(3):377-83. PubMed ID: 22395252
[TBL] [Abstract][Full Text] [Related]
44. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.
O'Connor OA; Lue JK; Sawas A; Amengual JE; Deng C; Kalac M; Falchi L; Marchi E; Turenne I; Lichtenstein R; Rojas C; Francescone M; Schwartz L; Cheng B; Savage KJ; Villa D; Crump M; Prica A; Kukreti V; Cremers S; Connors JM; Kuruvilla J
Lancet Oncol; 2018 Feb; 19(2):257-266. PubMed ID: 29276022
[TBL] [Abstract][Full Text] [Related]
45. Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review.
Donato EM; Fernández-Zarzoso M; Hueso JA; de la Rubia J
Onco Targets Ther; 2018; 11():4583-4590. PubMed ID: 30122950
[TBL] [Abstract][Full Text] [Related]
46. Brentuximab vedotin in real life, a seven year experience in patients with refractory/relapsed CD30+ T cell lymphoma.
Oberic L; Delzor F; Protin C; Perriat S; Laurent C; Grand A; Canonge JM; Borel C; Gauthier M; Ysebaert L; Puisset F
J Oncol Pharm Pract; 2021 Oct; 27(7):1730-1735. PubMed ID: 33100177
[TBL] [Abstract][Full Text] [Related]
47. Anaplastic large cell lymphoma, ALK-negative.
Ferreri AJ; Govi S; Pileri SA; Savage KJ
Crit Rev Oncol Hematol; 2013 Feb; 85(2):206-15. PubMed ID: 22789917
[TBL] [Abstract][Full Text] [Related]
48. Phase I clinical study of brentuximab vedotin (SGN-35) involving children with recurrent or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large cell lymphoma: rationale, design and methods of BV-HLALCL study: study protocol.
Sekimizu M; Iguchi A; Mori T; Koga Y; Kada A; Saito AM; Horibe K
BMC Cancer; 2018 Feb; 18(1):122. PubMed ID: 29390984
[TBL] [Abstract][Full Text] [Related]
49. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.
Pro B; Advani R; Brice P; Bartlett NL; Rosenblatt JD; Illidge T; Matous J; Ramchandren R; Fanale M; Connors JM; Yang Y; Sievers EL; Kennedy DA; Shustov A
J Clin Oncol; 2012 Jun; 30(18):2190-6. PubMed ID: 22614995
[TBL] [Abstract][Full Text] [Related]
50. Dermal xanthomatous infiltrates after brentuximab vedotin therapy in mycosis fungoides with large-cell transformation: A novel histologic finding.
Buchely N; Al-Rohil RN; Aung PP; Jour G; Torres-Cabala C; Prieto VG; Ivan D
J Cutan Pathol; 2018 May; ():. PubMed ID: 29806104
[TBL] [Abstract][Full Text] [Related]
51. Antibody-Drug Conjugate Made of Zoledronic Acid and the Anti-CD30 Brentuximab-Vedotin Exert Anti-Lymphoma and Immunostimulating Effects.
Morelli F; Matis S; Benelli R; Salvini L; Zocchi MR; Poggi A
Cells; 2024 May; 13(10):. PubMed ID: 38786084
[TBL] [Abstract][Full Text] [Related]
52. Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma.
Siddiqi T; Thomas SH; Chen R
Pharmgenomics Pers Med; 2014; 7():79-85. PubMed ID: 24672256
[TBL] [Abstract][Full Text] [Related]
53. Brentuximab Vedotin in CD30-Positive Lymphomas: A SIE, SIES, and GITMO Position Paper.
Zinzani PL; Corradini P; Gianni AM; Federico M; Santoro A; Vitolo U; Barosi G; Tura S
Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):507-13. PubMed ID: 26195435
[TBL] [Abstract][Full Text] [Related]
54. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data.
Horwitz SM; Scarisbrick JJ; Dummer R; Whittaker S; Duvic M; Kim YH; Quaglino P; Zinzani PL; Bechter O; Eradat H; Pinter-Brown L; Akilov OE; Geskin L; Sanches JA; Ortiz-Romero PL; Weichenthal M; Fisher DC; Walewski J; Trotman J; Taylor K; Dalle S; Stadler R; Lisano J; Bunn V; Little M; Prince HM
Blood Adv; 2021 Dec; 5(23):5098-5106. PubMed ID: 34507350
[TBL] [Abstract][Full Text] [Related]
55. Brentuximab vedotin for treatment of systemic T-cell lymphoma.
Chihara D; Oki Y
Expert Opin Biol Ther; 2014 Oct; 14(10):1519-26. PubMed ID: 25200691
[TBL] [Abstract][Full Text] [Related]
56. Systemic and primary cutaneous anaplastic large cell lymphoma: Clinical features, morphological spectrum, and immunohistochemical profile.
Kwatra KS; Paul PAM; Calton N; John JM; Cotelingam JD
South Asian J Cancer; 2017; 6(3):129-131. PubMed ID: 28975123
[TBL] [Abstract][Full Text] [Related]
57. Brigatinib in ALK-Positive ALCL after Failure of Brentuximab Vedotin.
Veleanu L; Lamant L; Sibon D;
N Engl J Med; 2024 Jun; 390(22):2129-2130. PubMed ID: 38865667
[No Abstract] [Full Text] [Related]
58. Brentuximab vedotin.
Deng C; Pan B; O'Connor OA
Clin Cancer Res; 2013 Jan; 19(1):22-7. PubMed ID: 23155186
[TBL] [Abstract][Full Text] [Related]
59. Safety and Efficacy of Brentuximab Vedotin in the Treatment of Classic Hodgkin Lymphoma.
Makita S; Maruyama D; Tobinai K
Onco Targets Ther; 2020; 13():5993-6009. PubMed ID: 32606807
[TBL] [Abstract][Full Text] [Related]
60. Anaplastic Lymphoma Kinase- and CD30-Positive Anaplastic Large-Cell Lymphoma of the External Auditory Canal.
Chen SL; Chan KC
Diagnostics (Basel); 2021 Jul; 11(7):. PubMed ID: 34359303
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
